These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 33409397)

  • 1. Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).
    Choudhary NS; Duseja A
    Transl Gastroenterol Hepatol; 2021; 6():2. PubMed ID: 33409397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics and epigenetics of NAFLD and NASH: Clinical impact.
    Eslam M; Valenti L; Romeo S
    J Hepatol; 2018 Feb; 68(2):268-279. PubMed ID: 29122391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
    Carlsson B; Lindén D; Brolén G; Liljeblad M; Bjursell M; Romeo S; Loomba R
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1305-1320. PubMed ID: 32383295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and Epigenetic Modifiers of Alcoholic Liver Disease.
    Meroni M; Longo M; Rametta R; Dongiovanni P
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis.
    Schmalz F; Fischer J; Innes H; Buch S; Möller C; Matz-Soja M; von Schönfels W; Krämer B; Langhans B; Klüners A; Soyka M; Stickel F; Nattermann J; Strassburg CP; Berg T; Lutz P; Nischalke HD
    JHEP Rep; 2023 Apr; 5(4):100684. PubMed ID: 36879887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the genetic backgrounds of patients with alcoholic liver disease and non-alcoholic fatty liver disease.
    Yamamoto K; Kogiso T; Taniai M; Hashimoto E; Tokushige K
    JGH Open; 2019 Feb; 3(1):17-24. PubMed ID: 30834336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.
    Dongiovanni P; Anstee QM; Valenti L
    Curr Pharm Des; 2013; 19(29):5219-38. PubMed ID: 23394097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD.
    Busca C; Arias P; Sánchez-Conde M; Rico M; Montejano R; Martín-Carbonero L; Valencia E; Moreno V; Bernardino JI; Olveira A; Abadía M; González-García J; Montes ML
    Front Pharmacol; 2022; 13():905126. PubMed ID: 36110512
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetics Is of the Essence to Face NAFLD.
    Meroni M; Longo M; Tria G; Dongiovanni P
    Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
    Lin YC; Chang PF; Chang MH; Ni YH
    Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease: a narrative review of genetics.
    Danford CJ; Yao ZM; Jiang ZG
    J Biomed Res; 2018 Nov; 32(5):389-400. PubMed ID: 30355853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
    Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
    Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of alcoholic liver disease and non-alcoholic steatohepatitis.
    Scott E; Anstee QM
    Clin Med (Lond); 2018 Apr; 18(Suppl 2):s54-s59. PubMed ID: 29700094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Screening via Sanger Sequencing of the Genetic Variants in Non-Alcoholic Fatty Liver Disease Subjects in the Saudi Population: A Hospital-Based Study.
    Alsaif F; Al-Hamoudi W; Alotaiby M; Alsadoon A; Almayouf M; Almadany H; Abuhaimed J; Ghufran N; Merajuddin A; Ali Khan I
    Metabolites; 2022 Dec; 12(12):. PubMed ID: 36557278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.